Smoking doesn't just damage your lungs.
Here's what it's quietly doing to your arteries.

Healthy

Open · clean · flowing

After Years of Smoking

Narrowed · plaque · clot-prone

Coronary artery comparison · Medical rendering

A 16-year study of more than 30,000 people in Japan uncovered an unexpected protective factor against the cardiovascular damage caused by smoking — and it's changing how we think about heart attack and stroke risk.

Most smokers know about the lung damage. The cancer warnings, the COPD, the persistent cough. What far fewer realise is that long before the lungs give out, smoking is doing something far quieter — and arguably more dangerous — to the network of arteries feeding the heart and brain.

The damage doesn't show up on a chest x-ray. There's no cough, no wheeze, no obvious symptom at all. By the time most people find out, it's because they've been wheeled into A&E with chest pain, or worse.

But over the past decade, a growing body of research — much of it coming out of Japan, where smoking rates remained high long after the West cleaned up — has started to map exactly what cigarettes do inside your bloodstream. And one finding in particular has pulled the attention of cardiologists worldwide.

What cigarettes actually do to your bloodstream

Every time you light up, your body responds to the chemicals in cigarette smoke as an injury. Inflammation rises. Blood vessels constrict. And — critically — your liver ramps up production of a sticky protein called fibrin.

Fibrin is what your body uses to form clots when you cut yourself. In normal amounts, it's lifesaving. But research has consistently shown that smokers carry up to three times higher fibrin levels in their blood than non-smokers — even when they're just sitting on the sofa.

Figure 1 · Thick blood vs healthy flow Side-by-side blood vessel comparison. On one side, fibrin-rich, viscous blood typical of heavy smokers — sticky, slow, and clot-prone. On the other, normal arterial flow.

The problem isn't the fibrin itself. It's what happens when too much of it accumulates. Excess fibrin makes your blood physically thicker — more viscous — and that thicker blood is far more likely to form the kind of dangerous clots that block coronary arteries or cut off blood supply to the brain.

This is the mechanism behind a sobering statistic: smokers are roughly twice as likely to suffer a heart attack as non-smokers, and the risk of ischaemic stroke roughly doubles too. Lung cancer gets the headlines. Cardiovascular events kill far more smokers.

Smokers don't just have damaged lungs. They have stickier, thicker, clot-prone blood — and that's the variable cardiologists are now most interested in. — Cardiovascular research summary, 2023

The Japanese paradox

Here's where the story takes an unexpected turn.

For most of the second half of the 20th century, Japan had one of the highest male smoking rates in the developed world. In the 1960s, more than 80% of Japanese men smoked. As recently as the early 2000s, that figure was still well over 50% — when most Western countries had already plummeted into the teens.

By every model used in Western cardiology, Japan should have been a heart-attack epidemic. It wasn't. In fact, despite the smoking, despite a rapidly modernising diet, Japan has maintained one of the lowest rates of coronary heart disease in the entire developed world — alongside one of the longest life expectancies on the planet.

The numbers are uncomfortable for anyone who's ever been told a Western diet and Western healthcare are the gold standard.

Look at the left-hand chart again. Americans die of ischemic heart disease at three and a half times the Japanese rate. British adults at almost three times. And yet Japan, with its decades of heavy smoking, lives on average five years longer than the average American.

For decades, that paradox bothered researchers. There were the obvious candidates — fish-rich diets, smaller portion sizes, more walking. But none of those fully explained the gap. So a team of cardiovascular epidemiologists started looking at something cultural that almost no Westerner ever eats: a fermented soybean dish called nattō.

Nattō · The 1,000-year-old breakfast A pungent, sticky fermented soybean dish that's been eaten daily across Japan since long before "cardiovascular health" was a phrase. It's also the only known dietary source of the enzyme nattokinase.

Nattō is divisive. It smells strong. The texture is famously polarising. But it has been a daily breakfast staple in much of Japan — particularly the Kantō region around Tokyo — for over a thousand years. And in 1980, a Japanese researcher named Dr Hiroyuki Sumi isolated the active compound responsible for one of nattō's most curious properties: it dissolves blood clots.

He named the enzyme nattokinase.

A 16-year study, 30,000 people, and one very surprising result

Dr Sumi's discovery sat in the academic literature for years before anyone seriously studied what it might do at the population level. Then, beginning in the 2000s, Japanese researchers launched what would become one of the largest and longest cardiovascular observational studies of its kind: tracking more than 30,000 adults over a 16-year period, comparing those who consumed nattokinase regularly with those who didn't.

The results, when they finally came in, raised eyebrows on both sides of the Pacific.

Participants who regularly consumed nattokinase showed a 25% lower risk of heart attack and a 33% lower risk of stroke compared to those who didn't. The effect held up after researchers controlled for diet, exercise, age, and — critically — smoking status.

Translation: nattokinase appeared to be doing something that partly cancelled out the cardiovascular damage caused by lifestyle factors most cardiologists consider non-negotiable. Including smoking.

How it works (and why it's relevant if you smoke)

Nattokinase is what biochemists call a fibrinolytic enzyme. The name tells you most of what you need to know: it breaks down (lyses) fibrin. The exact same sticky protein that smoking causes your body to overproduce.

What makes nattokinase particularly interesting in the context of smoking-related risk is that it appears to target the specific form of cardiovascular damage that smokers accumulate: thickened, fibrin-rich blood that's primed to clot. It doesn't reverse lung damage. It doesn't undo years of arterial inflammation overnight. But it does work directly on one of the main mechanisms by which smoking translates into heart attacks and strokes.

Outside Japan, nattokinase has slowly built a serious clinical evidence base — multiple peer-reviewed trials have shown reductions in blood pressure, improvements in blood viscosity, and dose-dependent reductions in fibrinogen levels. It is now one of the most studied natural cardiovascular ingredients on the market.

The problem with most nattokinase products on the market

Here's the part of the story that supplement brands generally don't want to talk about.

Nattokinase activity is measured in units called FU (fibrinolytic units). The dose used in most published clinical research is around 2,000 FU per day, with the most clinically meaningful results often reported at 4,000–6,000 FU. The label on a typical nattokinase capsule will state somewhere in that range.

But here's the catch: nattokinase is a fragile, heat-sensitive enzyme. If a manufacturer cuts corners during fermentation, drying, or encapsulation, the actual enzymatic activity in the finished bottle can be a fraction of what's printed on the label. And until very recently, almost no one was independently checking.

Earlier this year, our team commissioned independent third-party testing through SORA Labs — an ISO 17025:2017 accredited testing facility — on eight popular nattokinase brands sold in the UK and US. We weren't checking against our own product. We were simply asking: does what's on the label match what's in the bottle?

If you're taking a nattokinase supplement specifically to address the kind of cardiovascular risk we've been describing, this matters enormously. A bottle that delivers half its stated dose isn't a supplement — it's an expensive placebo.

Built on proof, not marketing claims Independently batch-tested · 5,000 FU per capsule (properly dosed) · GMP-manufactured in the UK.

Why we built NF Nattokinase

Natural Foundation Supplements is a small, family-run cardiovascular health brand. We manufacture everything in-house at our facility in Oxfordshire, UK. We do that for one reason: it's the only way we've found to control quality at every step of the process — and to be able to show you the evidence.

The team · Oxfordshire, UK Family-run, in-house manufactured. Every batch leaves the same building it was made in.

Our nattokinase is dosed at 5,000 FU per capsule. Every batch we produce is sent to an ISO 17025:2017 accredited laboratory for independent fibrinolytic activity testing. The most recent batch tested at 134% of label claim — 6,720 FU per capsule against the 5,000 FU stated. We publish the Certificate of Analysis for every lot, and you can scan the QR code on every bottle to view it.

To our knowledge, no other nattokinase supplement on the UK market publishes per-batch ISO 17025 testing. We started doing it because we got tired of watching the supplement industry promise things it couldn't prove, and because — as a family brand whose own customers are people in their fifties, sixties and beyond who are genuinely worried about heart attack and stroke risk — the stakes are too high to do anything else.

What's in the bottle (and what isn't)

A single capsule of NF Nattokinase contains pure nattokinase enzyme standardised to 5,000 FU. There are no proprietary blends, no buffering agents, no added "support" ingredients designed to make a small amount of the active compound look more impressive. The active dose is the active dose, and we test for it on every single lot.

It is suitable for vegans, free from gluten, soy isolates and added sugars, and manufactured in a UK facility audited to GMP standards.